Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Louis Mariotti

Otolaryngic Allergy Kingston, PA Doctor of Osteopathy

NPI 1437139300 CMS profile 336828

423 3Rd Ave, Suite C, Kingston, PA 18704

Open in the dashboard

General payments

$1,254

54 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Louis Mariotti of Kingston, PA is reported in the CMS Open Payments database as having received $1,254 across 54 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $192 6
2024 General $151 6
2023 General $123 5
2022 General $203 10
2021 General $144 8
2020 General $162 8
2019 General $279 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Louis Mariotti
  • Otolaryngic Allergy median
  • Middle half of Otolaryngic Allergy
  • National median

In program year 2025, general payments to Louis Mariotti were reported at $192. Among 69 Otolaryngic Allergy profiles paid that year, the median was $420 and the middle half received between $149 and $981.

Show as a table
Year Louis Mariotti Otolaryngic Allergy median Middle half National median
2019 $279 $206 $52–$646 $163
2020 $162 $158 $40–$529 $114
2021 $144 $225 $68–$696 $132
2022 $203 $364 $108–$1,004 $149
2023 $123 $272 $123–$1,038 $160
2024 $151 $416 $129–$1,844 $164
2025 $192 $420 $149–$981 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Acclarent, Inc $306 10 payments
  2. Regeneron Healthcare Solutions, Inc. $229 10 payments
  3. Genzyme Corporation $215 9 payments
  4. Aerin Medical Inc. $135 6 payments
  5. GlaxoSmithKline, LLC. $88 5 payments
  6. OptiNose US, Inc. $80 4 payments
  7. Intersect ENT, Inc. $53 3 payments
  8. Neurent Medical Limited $52 1 payment
  9. kaleo, Inc. $40 3 payments
  10. ALK-Abello, Inc $31 2 payments
  11. Other $26 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,254 54 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Inflammation And Immunology $201 9 payments
  2. DUPIXENT Immunology $197 8 payments
  3. RELIEVA SpinPlus NAV Balloon Sinusplasty System $102 3 payments
  4. TruDi $91 3 payments
  5. NUCALA $88 5 payments
  6. Xhance $80 4 payments
  7. VIVAER STYLUS $68 2 payments
  8. RHINAER STYLUS $68 2 payments
  9. SINUVA $53 3 payments
  10. NEUROMARK System $52 1 payment
  11. Other $389 19 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

289

Median for Otolaryngology: 297

Drug cost

$5,128

Median for Otolaryngology: $6,314

Branded share of claims

5.9%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mometasone Furoate Generic 43 $1,743
Neomycin-Polymyxin-Hc Neomycin/Polymyxin B/Hydrocort Brand 17 $897
Fluticasone Propionate Generic 41 $603
Ipratropium Bromide Generic 16 $533
Pantoprazole Sodium Generic 53 $476
Famotidine Generic 37 $463
Prednisone Generic 53 $151
Mupirocin Generic 18 $138
Ciprofloxacin Hcl Generic 11 $125

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$79,287

Medicare's payments for the services billed

Medicare patients

558

Average age 77

Services billed

2,157

337 women, 221 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Ischemic heart disease 29%
Diabetes 27%
Chronic kidney disease 24%
Atrial fibrillation 20%
Osteoporosis 18%
COPD 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $95
  • GENZYME CORPORATION $21
$115 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

54 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Otolaryngic Allergy in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record